Stanford



Julia Gesine Fricke

Postdoctoral Scholar, Radiology

Bio

BIO

Dr. Julia G. Fricke is a Swiss board-certified nuclear medicine physician-scientist and Postdoctoral Scholar in the Department of Radiology at Stanford University School of Medicine, supported by a Swiss National Science Foundation (SNSF) Postdoc.Mobility Fellowship.

Her research focuses on theranostics and the clinical translation of novel radiopharmaceuticals, with a particular interest in targeted radionuclide therapy and molecular imaging in oncology. During her clinical and research training at University Hospital Basel, Switzerland, she contributed to the first-in-human clinical evaluation of the somatostatin receptor antagonist [¹#¹Tb]Tb-DOTA-LM3 for neuroendocrine tumor therapy, as well as the clinical investigation of GLP-1 receptor PET/CT using [##Ga]Ga-DOTA-exendin-4 for insulinoma localization. Her research has been recognized with several distinctions, including the Marie Curie Award at EANM 2024 and the Young Authors Award at EANM 2026.

At Stanford, her research focuses on long-axial-field-of-view PET/CT and its potential to advance the clinical translation of emerging radiopharmaceuticals. Her long-term research interests include the development and clinical translation of innovative molecular imaging and targeted radionuclide therapy strategies.

HONORS AND AWARDS

- Young Authors Award, EANM (2026)
- SNSF Postdoc.Mobility Fellowship, Swiss National Science Foundation (2026)
- EANM Travel Award, Novartis (2026)
- Best Oral Presentation, SGNM (2024)
- Image of the Month, EJNMMI (2024)
- Marie Curie Award, EANM (2024)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Member, ENETS (2026 - present)
- Member, EANM (2024 - present)
- Member, SGNM (2021 - present)

PROFESSIONAL EDUCATION

- Doctor of Medicine, Ludwig Maximilian Universitat Munchen (2022)
- Staatsexamen, Ludwig Maximilian Universitat Munchen (2020)

- Fellowship, University Hospital Basel, Switzerland , Radiology (2026)
- Board Certification, Swiss Medical Association , Nuclear Medicine (2026)
- Residency, University Hospital Basel, Switzerland , Nuclear Medicine (2024)
- MD, Ludwig-Maximilians-University, Munich, Germany , Medicine (2020)

STANFORD ADVISORS

- Andrei Iagaru, Postdoctoral Faculty Sponsor

LINKS

- LinkedIn: https://www.linkedin.com/in/julia-g-fricke
- ResearchGate: https://www.researchgate.net/profile/Julia-Fricke-4?ev=hdr_xprf

Publications

PUBLICATIONS

- **Targeted β--Particle Plus Conversion and Auger-Electron Therapy with 161Tb-Labeled Somatostatin Receptor Antagonist DOTA-LM3: A Phase 0 Study.** *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*

  Fricke, J. G., Westerbergh, F., McDougall, L., Favaretto, C., Christ, E., Nicolas, G. P., Geistlich, S., Schmid, D. E., Borgna, F., Fani, M., Bernhardt, P., van der Meulen, N. P., Müller, et al

  2026; 67 (3): 416-422

- **First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([161Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum.** *European journal of nuclear medicine and molecular imaging*

  Fricke, J., Westerbergh, F., McDougall, L., Favaretto, C., Christ, E., Nicolas, G. P., Geistlich, S., Borgna, F., Fani, M., Bernhardt, P., van der Meulen, N. P., Müller, C., Schibli, et al

  2024; 51 (8): 2517-2519

- **⁶⁸Ga-DOTA-exendin-4 PET/CT for insulinoma localization in patients with negative or inconclusive conventional imaging** *JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM*

  Fricke, J. G., Laubner, K., Schildmeijer, M., Menz, L., Wojsa, C., Meyer, P. T., Seufert, J., Wild, D., Christ, E., Freitag, M. T.

  2026; 111 (11): 3163-3171

- **Systematic review and meta-analysis of the efficacy and safety of [177Lu]Lu-edotreotide ([177Lu]Lu-DOTATOC) for the treatment of neuroendocrine tumors.** *Journal of neuroendocrinology*

  Baum, R. P., Fricke, J. G., Ruhwedel, T., Amthauer, H., Azorin-Vega, E. P., Hörsch, D., Laudicella, R., Maheshwari, V., Walter, M. A., Polack, B. D., Spiegl, S. F., Nicolas, G. P.

  2026; 38 (1): e70103

- **Bridging physics and practice: evaluating sensitivity, septal penetration, and detector dead time in terbium-161 gamma-camera imaging** *EJNMMI PHYSICS*

  Westerbergh, F., Mcdougall, L., Ritt, P., Fricke, J. G., van der Meulen, N. P., Mueller, C., Schibli, R., Wild, D., Bernhardt, P.

  2025; 12 (1)

- **Comparison of the tolerability of 161Tb- and 177Lu-labeled somatostatin analogues in the preclinical setting.** *European journal of nuclear medicine and molecular imaging*

  Busslinger, S. D., Mapanao, A. K., Kegler, K., Bernhardt, P., Flühmann, F., Fricke, J., Zeevaart, J. R., Köster, U., van der Meulen, N. P., Schibli, R., Müller, C.

  2024; 51 (13): 4049-4061